February 21, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, John M. Pagel, MD, PhD, discusses the case of a patient with diffuse large B-cell lymphoma who is not eligible for transplant.
February 21, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Scott Tykodi, MD, PhD, discussed the data supporting various treatment options for renal cell carcinoma with participants.
February 20, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Ruben Mesa, MD, discussed risk assessment and management of myeloproliferative neoplasms.
February 19, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.
February 18, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.
February 18, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.
February 17, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Jennifer L. Atlas, MD, discussed the case of a patient with infiltrative basal cell carcinoma with participants.
February 17, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Rachel N. Grisham, MD, discussed clinical trials of different PARP inhibitors for patients with ovarian cancer.
February 16, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Uday R. Popat, MD, discussed the approaches to identifying and managing graft-vs-host disease.
February 16, 2022
Clinical Articles
During a Targeted Oncology case-based roundtable event, Roy S. Herbst, MD, PhD, and Joshua K. Sabari, MD, discussed molecular testing and the use of immune checkpoint inhibitors with participants.
February 15, 2022
Clinical Articles
During a Targeted Oncology live virtual event, Javier L. Munoz, MD, MBA, discussed third-line treatments for DLBCL including chimeric antigen receptor T-cell therapy and targeted treatments.